[Form 4] Elevation Oncology, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller’s name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Positive

• Sale represents only ~0.15 % of outstanding shares, indicating minimal dilution or ownership impact.
• No other insider sales reported in the prior three months, reducing concerns of a broader disposal trend.

Negative

• Insider intends to sell US$18.94 million in stock, which can be perceived as a negative sentiment signal.
• Filing omits the seller’s identity and relationship to MEDP, limiting transparency for investors.

Insights

Securities Analyst

TL;DR: $18.9 M sale (0.15 % float) is modest; neutral-to-slightly negative signal given missing seller details.

The filing flags an insider-level disposition but the absolute and relative sizes are small, so dilution and control effects are negligible. Absence of past-90-day sales suggests no ongoing liquidation trend. However, lack of disclosure around the seller and any 10b5-1 plan limits transparency, preventing investors from evaluating whether the move is routine diversification or reflects a less favorable outlook. Until identity and context are clarified, the market impact should remain muted, but risk-averse investors may view any insider sale as a cautionary note.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Furlong Tammy

(Last) (First) (Middle)

C/O ELEVATION ONCOLOGY, INC.

101 FEDERAL STREET, SUITE 1900

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elevation Oncology, Inc. [ ELEV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2025		U		37,957(1)(2)	D	$0.36	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.09	07/23/2025		D			79,327	(3)	05/06/2031	Common Stock	79,327	$0	0	D
Stock Option (Right to Buy)	$3.09	07/23/2025		D			79,327	(3)	06/02/2031	Common Stock	79,327	$0	0	D
Stock Option (Right to Buy)	$3.31	07/23/2025		D			35,000	(3)	02/29/2032	Common Stock	35,000	$0	0	D
Stock Option (Right to Buy)	$0.75	07/23/2025		D			52,500	(3)	01/05/2033	Common Stock	52,500	$0	0	D
Stock Option (Right to Buy)	$0.98	07/23/2025		D			28,800	(3)	02/14/2033	Common Stock	28,800	$0	0	D
Stock Option (Right to Buy)	$1.51	07/23/2025		D			53,433	(3)	07/11/2033	Common Stock	53,433	$0	0	D
Stock Option (Right to Buy)	$2.77	07/23/2025		D			225,000	(3)	02/14/2034	Common Stock	225,000	$0	0	D
Stock Option (Right to Buy)	$0.6717	07/23/2025		D			275,000	(3)	02/14/2035	Common Stock	275,000	$0	0	D

Explanation of Responses:

1. Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

2. [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

3. As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration.

	/s/ Robert Yang, Attorney-in-Fact	07/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Medpace (MEDP) shares are being sold under this Form 144?

The filing covers 41,801 common shares of Medpace Holdings, Inc.

What is the dollar value of the proposed MEDP share sale?

The aggregate market value is approximately US$18.94 million.

What percentage of Medpace’s outstanding shares does the sale represent?

It equates to about 0.15 % of the 28.09 million shares outstanding.

When is the anticipated sale date for the MEDP shares?

The approximate sale date listed is 07/24/2025.

Were any MEDP shares sold by this insider in the past three months?

No; the filing states “Nothing to Report” for prior 3-month sales.

Is the trade linked to a Rule 10b5-1 plan?

The Form 144 does not specify whether the sale is under a 10b5-1 trading plan.